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Abstract We have previously shown that an N-glycosylation
site of N306 of HIV-1 gp120 is not necessary for the HIV-1
infectivity but protects HIV-1 from neutralising antibodies. In
contrast Nakayama et al. [FEBS Lett. (1998) 426, 367^372],
using a virus with an identical V3 region, suggested that
elimination of this particular glycan reduced the ability of
T-tropic HIV to bind to CXCR4 and hence its ability to infect
T cell lines. We therefore re-examined the ability of a mutant
virus, lacking the N306 glycan, to replicate in various types of
cells and found no change in co-receptor usage for mutant virus.
The ability of mutant virus to replicate or to induce syncytia in
infected cells was similar to that of wild type virus. These results
corroborate our original observation, confirming that the induced
mutation in the N306 glycosylation site neither impairs nor
improves the ability of mutant virus to replicate in permissive
cells.
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1. Introduction
The V3 region of the major glycoprotein, gp120, speci¢ed
by human immunode¢ciency virus type 1 (HIV-1) is an im-
portant factor in several aspects of the viral pathogenesis.
This region constitutes the principal neutralisation domain
(PND), harbouring extremely type-speci¢c neutralisation epit-
opes, where immunity to one HIV-1 variant via antibodies to
PND is not su⁄cient for neutralisation even of a closely re-
lated virus strain [1,2]. In addition, the V3 region together
with other parts of gp120 determines viral tropism for di¡er-
ent permissive cell types [3^6]. Thus, cells of the monocyte/
macrophage lineage and CD4-positive T-cells constitute two
classes of target cells where the presence of one type of che-
mokine receptor, CCR5, determines macrophage tropism and
another, CXCR4, determines T-cell tropism by aiding subse-
quent early interactions after the binding between HIV-1 and
CD4 [7,8].
The di¡erent HIV-1 variants may not always appear to be
strictly macrophage-tropic or strictly T-cell-tropic viruses, and
several dual-tropic HIV-1 strains able to replicate in macro-
phages as well as in T-cells have been described [9^11]. Ini-
tially, it was described that dual-tropic viruses were able to
bind both to CXCR4 of T-cells and to chemokine receptors of
the CCR class of macrophages [11]. Recently it was described
that also strictly CXCR4-binding HIV variants under certain
conditions may be dual-tropic. Most cells of the monocyte/
macrophage lineage carry CXCR4 molecules on the cell sur-
face in addition to CCR5, normally acting as a secondary
receptor for macrophage-tropic virus, but these CXCR4 mol-
ecules are not su⁄cient to promote infection by most HIV-1
variants only binding to CXCR4 [12]. For the new type of
dual-tropic viruses this block is circumvented by an increased
a⁄nity for CXCR4, bypassing the normal restriction of rep-
lication of T-tropic HIV-1 [13]. The increased a⁄nity for
CXCR4 of such dual-tropic HIV-1 variants permits them to
infect cells in a CD4-independent way.
We and others have shown that the N-linked glycan at-
tached to N306 of the V3 loop plays a pivotal role in deter-
mining the accessibility of this region for neutralising anti-
bodies. Thus, a mutant virus lacking this particular glycan
is neutralised several hundred times more e⁄ciently than is
the wild type virus [14^16]. Recent data indicate that the
shielding e¡ect by the N306 glycan on the PND is restricted
to protecting gp120 in oligomers from attack by anti-V3 anti-
bodies, whereas monomeric gp120 is fully accessible even in
the presence of the glycan [17]. This raises the question if the
N306 also can modulate V3-dependent functions of gp120
such as cellular tropism. A recent paper by Nakayama et al.
[18] suggested that elimination of this particular glycan would
reduce the ability of T-tropic HIV to bind to CXCR4 and
hence its ability to infect T-cell lines. These results appear
to be at variance with both our data [16] and the data of
Back et al. [14]. In the present paper, we extend our studies
on the role of the N306 glycan for the biological properties of
gp120. Speci¢cally we asked the following questions: (i) Does
the increased exposure of the V3 region induced by elimina-
tion of the N306 glycan expand the chemokine receptor use of
strictly CXCR4-binding HIV to include also CCR5? (ii) If
not, will the induced change in glycosylation induce dual-
tropic behaviour due to an increased a⁄nity for CXCR4?
(iii) Finally we sought to evaluate if the loss of the glycan
resulted in an opposite behaviour, as suggested by Nakayama
et al. [18].
2. Materials and methods
2.1. HIV-1 clones
In most experiments we used an infectious clone of HIV-1, HIV-
1A308, lacking the glycosylation site at Asn306, generated by subject-
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ing the proviral plasmid vector pBRU-2, containing the entire HIV-
1BRU genome, to site-directed mutagenesis [15,16]. The transfection
and subsequent preparation of stock suspensions of mutant or wild
type virus for further experiments were done under standardised con-
ditions to ensure that no di¡erences in spontaneous inactivation and
degeneration of the two virus preparations occurred [19]. The muta-
tion was con¢rmed by sequencing using the chain termination meth-
od, and the sequences were read in an ABI Prism automated capillary
sequence reader (Applied Biosystems, Foster City, CA, USA) and
processed using the Sequence Navigator Software (Applied Biosys-
tems). The lack of one glycosylation site was further con¢rmed by
SDS-PAGE of [3H]GlcN-labelled mutant and wild type gp120 after
immunoprecipitation (Fig. 1).
2.2. Cells
The CD4+ lymphocyte cell line H9 (ATCC HTB-176) [20,21] was
cultured at 37‡C and 5% CO2, in RPMI 1640 supplemented with 20%
heat-inactivated foetal calf serum (FCS), 2 WM glutamine, 100 IU of
penicillin per ml, 20 Wg gentamicin per ml and 100 IU streptomycin
per ml. The CD4+ lymphocyte cell line MT-2 [22] was maintained in
RPMI 1640 supplemented with 10% heat-inactivated FCS, 100 IU
penicillin per ml, 20 Wg gentamicin per ml and 100 IU streptomycin
per ml. The monocytic cell line U937 (ATCC CRL 1593) was main-
tained in RPMI 1640 containing 10% heat-inactivated FCS, 2 WM
glutamine, 100 IU of penicillin per ml, 20 Wg gentamicin per ml
and 100 IU streptomycin per ml. HOS-CD4 cells expressing
CXCR4 (HOSCD4-CXCR4), CCR5 (HOSCD4-CCR5) and pBABE-
puro (HOSCD4-pBABE) were obtained through the NIH AIDS Re-
search and Reference Reagent Program and propagated as described
by Deng et al. [23] and Laundau et al. [24]. HeLa-CD4 cells [25]
were maintained in DMEM10 supplemented with 1 Wg/ml G418
(Geneticin, Gibco) and 293 cells [26] were maintained in DMEM10.
Peripheral blood mononuclear cells (PBMCs) were obtained from
healthy blood donors. All cell cultures were maintained at 37‡C in
5% CO2.
2.3. Preparation of reporter virus by env trans-complementation
The 2.1 kb KpnI-BamHI fragment of the HIV-1 env trans-comple-
mentation vector pSVIIIenv [27] was exchanged with the correspond-
ing fragments of pBRU-2 and pBRU-A308 env ORF resulting in the
vectors pSV-BRU and pSV-BRU-A308, respectively, using general
DNA subcloning techniques. An env-defective derivative of
pSVIIIenv, pSV-dBgl, containing a 580 bp out of frame deletion with-
in the env gene was used as a mock plasmid to determine background
CAT activity. Virus capable of single-cycle replication was then gen-
erated by cotransfecting as indicated either COS-1 or 293 cells with
env-expressing plasmid and pHXBvenvCAT (an env-defective HIV
expression vector containing a chloramphenicol acyltransferase
(CAT) gene in the nef open reading frame of the HIV-1 genome
[27]). COS-1 cells were transfected by lipofection using Lipofectin
(Gibco) as previously described [28]; 293 cells were transfected by
calcium phosphate precipitation exactly as described elsewhere [29].
Twenty-four hours after transfection culture medium was changed
and after an additional 48 h virus was harvested and clari¢ed by
membrane ¢ltration (45 Wm). The virus particles thus generated
were designated BRU and BRU-A308, respectively, to distinguish
them from the corresponding fully infectious virus variants HIV-
1BRU and HIV-1A308, also used in the present study.
2.4. Leu3a inhibition of A308 and BRU
A308 and BRU particles were produced by transfection of 293 cells
as described above. Monoclonal antibody (mAb) Leu3a, speci¢c for
the gp120-binding domain of CD4 [30], in ¢vefold dilution was added
to HeLa-CD4 [25] cultures in 24 well cluster dishes, containing 400 Wl
of Dulbecco’s modi¢cation of Eagle’s MEM. Media from BRU- or
A308-producing 293 cells were passed through a 45 Wm membrane
¢lter and 400 Wl of BRU or A309 suspension was added to the Leu3a-
containing HeLa-CD4 wells. The cultures were incubated at 37‡C for
3 days. Subsequently, the HeLa-CD4 cells were lysed and assayed for
CAT activity as previously described [28].
2.5. Single-cycle infectivity assay
Single-cycle replication conditions was ascertained by env trans-
complementation by pSV-BRU and pSV-BRU-A308 in COS-1 cells
as described by Helseth et al. [27] and as modi¢ed by Lund et al. [28].
HIV-1 infection of the target cell line, MT4, was normalised to trans-
fection e⁄ciency of HIV-1 producer cells using CAT activity of COS-
1 cells as the normalisation factor. COS-1 cells were lysed in 400 Wl
Reporter lysis bu¡er (Promega) after harvest of reporter virus super-
natant.
2.6. Antigen production kinetics assay
H9 cells were transfected with pBRU-2 or pBRU-A308 by DEAE-
dextran [0.3U106 cells/ml in RPMI 1640 (Gibco); DNA 2 Wg/ml;
DEAE dextran (MW 500 000; Pharmacia Upjohn, Stockholm, Swe-
den) 7 Wg/ml; incubation at 37‡C for 45 min]. Cells were then washed,
and seeded on 24 well tissue culture plates (Nunclon, Roskilde, Den-
mark) in RPMI 1640 containing 10% FCS and viral antigen was
allowed to peak (3 weeks culture). Then uninfected H9 cells were
mixed with 1/500 cells from infected cultures and seeded on 6 well
tissue culture plates (Nunclon) in 2.5 ml at 0.1U1036 cells/ml. Sam-
ples of supernatant were harvested daily (day 5 to day 11) and cul-
tures were diluted 1:5 on day 4 and day 7. HIV-1 antigen was quan-
ti¢ed by an in house ELISA based on polyclonal antibodies obtained
from HIV-1 infected patients [31]. Frozen stock dilutions of super-
natants from H9 cells chronically infected with HIV-1LAI were used as
internal standards [32].
2.7. Infectivity assay
Mutant and wild type virus variants were produced and titrated in
H9 cells according to the principle of Reed and Muench to determine
TCID50 of each virus [33]. Subsequently, 1600 TCID50 of each virus
variant were inoculated to 7.5U105 U937 cells in quadruplicate in
24 well cell culture plates (1.5 ml medium per well) and titrated at
¢vefold dilutions. The same virus variants were also analysed in MT4,
H9 and PBMC cultures, using 100 TCID50 per culture well. The
infected cultures were incubated at 37‡C, and virus antigen (p24) in
culture supernatant was measured at various times post infection, as
described by Valhne et al. [34]. Similar conditions were used for in-
fection of PBMC.
2.8. Syncytium formation assay
The extent of syncytium formation by the mutant and wild type
virus variants was determined mainly according to Watkins et al. [35].
H9 cells were infected with HIV-1BRU or HIV-1A308 as described
above. After the infected cell cultures had passed the syncytium for-
mation phase, but were still expressing high levels of p24 in culture
supernatant, infected cells were washed once in culture medium and
mixed with uninfected H9 cells (ratio of infected:uninfected cells 1:5).
The number of syncytia in cell cultures was determined 48 h after
mixing infected and uninfected cells. mAb NEA-9205 (1.5 Wg/ml)
and a pool of sera from ARC patients (corresponding to 25 Wl serum)
were used in blocking experiments (adsorption at 37‡C for 1 h) to
control the speci¢city of syncytia formation.
3. Results
First we investigated if the increased exposure of the V3
region due to loss of the N306 glycan resulted in expanded
co-receptor usage of a prototype T-tropic virus. Chimeric re-
porter virus BRU-A308, lacking the glycosylation site at
N306, and corresponding wild type reporter virus BRU,
both expressing CAT activity when taken up by permissive
cells, were produced by trans-complementation as described
by Lund et al. [28]. It was found that both BRU and BRU-
A308 produced CAT activity after infection of CD4-CXCR4-
expressing HOS cells whereas corresponding CCR5-expressing
cells were refractive to BRU as well as BRU-A308 (Table 1).
The infection of HOSCD4-CXR4 by BRU and BRU-A308
was blocked equally well by the anti-CD4 antibody Leu3a,
indicating that both mutant and wild type virus were depend-
ent on CD4 for infection of permissive cells (Fig. 2a). Alto-
gether, these data demonstrated that increased exposure of the
V3 loop in a T-tropic HIV strain does not confer CCR5-de-
pendent tropism on such viruses. Moreover, our data did not
suggest that the CXCR4-dependent entry of the carbohydrate-
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de¢cient mutant was impaired compared to wild type virus as
has been suggested by Nakayama et al. [18].
The increased uptake rate of BRU-A308 in CXCR4-ex-
pressing HOS cells could possibly re£ect a higher fusion ca-
pacity of mutant virus compared with wild type virus. Next,
we therefore investigated if the N-linked glycan of N306 in-
terfered with the ability of virus-infected cells to form syncytia
according to the method of Watkins et al. [35] (Table 2).
These results demonstrated that HIV-1A308 did not induce
syncytium formation signi¢cantly better than did HIV-1BRU,
suggesting that the N306 glycan is not responsible for inter-
ference with post-binding interactions necessary for syncytium
formation. However, mAb NEA-9205, binding to a V3 epit-
ope, blocked the syncytium formation capacity of HIV-1A308
to a higher extent than that of HIV-1BRU, which was not
unexpected owing to the possible involvement of the V3 re-
gion in HIV-induced fusion events [36].
These results did thus not exclude the possibility that elim-
ination of the N308 glycan could facilitate HIV-1 infection of
normally low-permissive CXCR4-positive cells in other ways,
resulting in an expansion of the range of permissive cells. To
determine if the elimination of the N306 glycosylation site
resulted in a switch to dual tropism via the alternative mech-
anism, i.e. by enhanced binding to CXCR4, we infected a
clone of the monocytoid cell line U937, normally refractory
to T-tropic HIV [12] variants, with HIV-1A308 or HIV-1BRU.
As a positive control, we used HIV-1IIIB, clone strain New
York, readily infecting U937 cells (Bolmstedt et al., unpub-
lished). Although a high dose of virus (500 TCID50 per cul-
ture) was used, we found that neither HIV-1A308- nor HIV-
1BRU-infected U937 cells produced any detectable amounts of
p24 antigen. In contrast, a marked increase in p24 antigen
production in B24-infected cells was observed on day 14
(Fig. 2b). These data show that elimination of the N306 gly-
can is not su⁄cient to introduce tropism for monocytoid cell
lines such as U937 in a CXCR4-dependent manner.
To determine whether the phenomenon described by Na-
kayama et al. [18], i.e. that elimination of the N306 glycan
should result in a decrease in the ability of HIV-1 to replicate
in normal immortalised T-cell lines, we analysed the kinetics
of mutant and wild type virus infection in several ways. In the
¢rst series of experiments, we used BRU and BRU-A308 in a
single-cycle HIV-1 replication assay, using the trans-comple-
mentation system of Helseth et al. [27]. The envelope-defective
HIV-1 reporter vector, pHXBvenvCAT, was cotransfected
with the envelope expression vectors pSV-BRU and pSV-
Fig. 1. RIPA and SDS-PAGE of immunoprecipitated gp120 from
culture media of H9 cells infected with HIV-1BRU (lane A) or HIV-
1A308 (lane B). The positions of molecular weights are indicated in
the ¢gure.
Table 1
Co-receptor usage of HIV-1A308
HIV constructa Target cell CAT signal (cpm)
BRU HOS-CD4-CCR5 719
167
A308 HOS-CD4-CCR5 1 003
523
BRU HOS-CD4-Fusin 17 430
18 380
A308 HOS-CD4-Fusin 32 849
39 109
BRU HOS-CD4-pBABE 224
285
A308 HOS-CD4-pBABE 877
803
BRU HeLa-CD4 18 686
16 788
A308 HeLa-CD4 30 214
29 227
aCarried out essentially as described by Lund et al. [28].
Fig. 2. a: Leu3a neutralisation-dependent neutralisation of HIV-1BRU (circles) and of HIV-1A308 (triangles). b: Lack of replication of HIV-1A308
and HIV-1BRU in monocytoid U937 cells. U937 cells were infected with 1600 TCID50 of HIV-1IIIB (strain B24), HIV-1A308, or HIV-1BRU. The
concentration of p24 antigen (arbitrary units) was measured at di¡erent times as indicated in the ¢gure. c: Single-cycle replication of HIV-1.
HIV-1 env trans-complementation was performed using the envelope expression vectors pSV-BRU and pSV-BRU-A308, derived from
pSVIIIenv [27]. CAT activity of target cells, MT4, was normalised to CAT activity determined in the transfected producer cells, COS-1, in or-
der to correct for di¡erences in transfection e⁄ciency. Results of two separate experiments are shown.
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BRU-A308 into COS-1 cells by lipofection. After 48 h the
resultant HIV-1 supernatant was transferred to MT4 cells,
and the resultant infection (determined as CAT activity) was
determined and normalised to transfection e⁄ciency of the
COS-1 cells. The CAT activity determined in COS-1 cells
following harvest of HIV-1 supernatant was used as the nor-
malisation factor. We found that infectivity of BRU and
BRU-A308 envelope in MT4 cells was almost identical by
this assay (Fig. 2c).
A similar result was obtained also when replication of HIV-
1A308 and HIV-1BRU was compared in MT2 cells over 20 days
(Fig. 3a). Thus, both HIV-1BRU and HIV-1A308 displayed es-
sentially congruent growth curves, reaching a maximum of
produced p24 on day 15. Both these results demonstrated
that the induced mutation in HIV-1A308 did not change the
ability of HIV-1 to replicate in HTLV-1 transformed cells
such as MT4.
We also performed a comparison in H9 cells of HIV-1
antigen kinetics between BRU and A308. Uninfected H9 cells
were inoculated with 500 times less H9 cells, transfected with
pBRU2 and or pBRUA308, and cultured for 11 days (Fig.
3b). Linear regression of the logarithmic plot of HIV-1 anti-
gen (day 6 to day 9) showed no gross di¡erence between the
calculated linear coe⁄cients of BRU (0.73 þ 2) and BRU-
A308 (0.65 þ 0.16) [95% con¢dence limits indicated]. Finally
we determined whether the long-term replication kinetics in
H9 (Fig. 3c) and diploid PBMC (Fig. 4) was a¡ected by elim-
ination of the N306 glycan. No signi¢cant di¡erence in the
replication kinetics was observed between mutant virus and
wild type virus in these experiments.
4. Discussion
We and others have demonstrated a key role of the N306
N-linked glycan in shielding the tip of the V3 region from
neutralising monoclonal and polyclonal antibodies
[14,15,29]. Owing to the critical role of this gp120 region, it
is reasonable that elimination of this glycan would result in a
virus with altered growth properties. Although there is evi-
dence that elimination of other N-glycosylation sites in
gp120 could change the three-dimensional conformation of
the glycoprotein [37], all available data suggest that elimina-
tion of the glycosylation site at A308 results in increased ex-
posure of the V3 region of gp120 oligomers, but without any
detectable change in the antigenic conformation. This conclu-
sion stems from the observations that several polyclonal and
monoclonal antibodies to the V3 region, prepared after im-
munisation with monomeric wild type gp120, bound several
times better to mutant gp120 oligomers than to corresponding
Fig. 3. a: Long-term replication of HIV-1A308 and HIV-1BRU in MT2 cells. About 100 TCID50 HIV-1A308 or HIV-1BRU was added to each cul-
ture well. The concentration of p24 antigen (arbitrary units) was measured at di¡erent times as indicated in the ¢gure. b: HIV-1 antigen pro-
duction analysis in H9 cultures inoculated at day 0 with 1/500 cells infected with either BRU (bold line; solid circles) or BRU-A308 (thin line;
open triangles). Two parallel inoculations were performed for each viral isolate. Antigen is determined as arbitrary units (AU) and depicted
logarithmically. Cell cultures were diluted 1:5 on day 4 and day 7 and the measured HIV-1 antigen was subsequently multiplied with the accu-
mulated dilution factor (5U day 5^7; 25U day 8^11). Inset: Linear regression of the data for BRU (solid line) and BRU-A308 (thin line). c:
Long-term replication of HIV-1A308, and HIV-1BRU in H9 cells. About 100 TCID50 HIV-1A308 or HIV-1BRU was added to each culture well.
The concentration of p24 antigen (arbitrary units) was measured at di¡erent times as indicated in the ¢gure.
Table 2
Syncytium induction of HIV-1BRU and HIV-1A308 in H9 cells
Virus/cell Medium NEA-9205 ARC serum
HIV-1BRU/H9 48 17 3
45 19 2
HIV-1A309/H9 45 7 0
44 5 0
H9 0 0 0
0 0 0
Data shown as number of syncytia per well (n = 2) of infected H9
cells 48 h post infection.
Fig. 4. Long-term replication of HIV-1BRU and HIV-1A308 in
PBMC. About 100 TCID50 HIV-1A308 or HIV-1BRU was added to
each culture well. The concentration of p24 antigen (arbitrary units)
was measured at di¡erent times as indicated in the ¢gure.
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wild type aggregates. In contrast, wild type and mutant mono-
meric gp120 bound equally well to antibodies to V3 [17,29].
Therefore, the expected change, if any, as to replication e⁄-
ciency introduced by elimination of the N-glycosylation site at
A308 would be an increased growth rate as a consequence of
increased exposure of gp120 domains involved in the early
interactions between HIV-1 and its host cell.
With this background, the result of Nakayama et al. [18] is
surprising as they suggest a signi¢cant impairment of replica-
tion e⁄ciency of mutant virus, lacking the N306 glycan. One
explanation suggested by Nakayama et al. [18] for the discrep-
ancy between their results and the results obtained in our
laboratory [15,16] and by Back et al. [14] is that the di¡erence
is subtle and not observable in short-term replication experi-
ments. However, in the present paper, we extended the obser-
vation period to saturation at 20 days post infection using the
same multiplicity of infection as Nakayama et al. [18] without
observing any detectable di¡erence between mutant and wild
type virus. Moreover, the experiments performed on the sin-
gle-round replication did not reveal any di¡erence in replica-
tion rate between mutant and wild type virus.
One possible explanation for the discrepancy between the
results of the present paper and those of Nakayama et al. [18]
is that these authors introduced relatively large amino acid
changes, when eliminating the N-glycosylation site at N306.
Thus, for one mutant the uncharged polar N306 was replaced
by a positively charged His and for other mutants uncharged
polar Thr308 was changed to an isoleucine with a large hydro-
phobic side chain, which should be compared with our strat-
egy where Thr306 was changed to Ala, with a small hydro-
phobic side chain only. In other words, the e¡ects observed by
Nakayama et al. [18] could be caused by the prominent chem-
ical di¡erence introduced in the amino acid side chains with-
out any involvement of the N-linked glycan. In fact, we re-
cently showed that replacing a Thr of a glycosylation site of
the herpes simplex virus glycoprotein C by an isoleucine re-
sulted in a prominent change in its binding behaviour without
involving the glycan itself [38]. It should be pointed out that
the wild type virus used in our study had the same amino acid
sequence over the entire V3 region as strain NL41, used in the
study by Nakayama et al. [18].
This would also suggest that the second phenomenon ob-
served by Nakayama et al., i.e. that clinical HIV-1 isolates
lacking the N308 glycan often contain an additional amino
acid substitution in the tip of the V3 region, is of passenger
nature and not a compensation for decreased CXCR4 binding
suggested by these authors. Rather, this could re£ect our ob-
servation [17] that mutant virus lacking the N308 glycan be-
came two orders of magnitude more susceptible than corre-
sponding wild type virus to neutralisation by anti-V3
antibodies and that escape mutants with regained resistance
frequently occurred where amino acids within or close to the
V3 region were changed to basic ones similar to the ¢ndings
of Nakayama et al. [18].
The present data demonstrated that the increased exposure
of the V3 region in intact virus particles did not enhance the
infectivity of mutant HIV-1A308 in immortalised cell lines nor
did it alter the fusion capacity in terms of syncytium forma-
tion. It is, however, noteworthy that the syncytium formation
activity in HIV-1A308-infected cells was signi¢cantly more sus-
ceptible to neutralisation by anti-V3 antibodies compared
with correspondingly HIV-1BRU-infected cells. This result sug-
gests that the N306 glycan sterically a¡ects the gp41/gp120
domains responsible for fusion at least to some extent. How-
ever, the fact that the general infectivity neither in short-term
nor in long-term propagation is a¡ected by the mutation sug-
gests that the fusion function such as observed in syncytium
formation is not a rate-limiting step in the viral infection of
permissive immortalised or diploid target cells. Altogether,
our results suggest that the conclusion of Nakayama et al.
[18], that the V3 glycan of HIV-1 in analogy with correspond-
ing V3 glycan of SIVmac [39] constitutes a strong determinant
for host cell range, may not be universal.
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